Therefore, it will be important to identify the patient subsets with ALL where BET inhibitors may be efficacious as well as using them in combination with agents such as HDAC inhibitors so that they may be used at lower doses to avoid toxicity. Here, HDAC9 is linked to acute lymphoblastic leukemia.